ALPHA 1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA 1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA 1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug ARO-AAT shows promise in early safety trial for rare lung disease
Disease control CompletedThis early-stage study tested the safety and how the body processes ARO-AAT in 45 healthy adults. The drug aims to lower abnormal protein levels that cause lung and liver damage in people with Alpha-1 Antitrypsin Deficiency. By focusing on safety first, this trial lays groundwork…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 11:49 UTC
-
New drug shows promise for rare liver condition
Disease control CompletedThis study tested a new drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The goal was to see if the drug is safe and can reduce harmful protein buildup in the liver. Participants received multiple doses of t…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 11:34 UTC
-
New drug shows promise in lowering harmful protein in rare liver disease
Disease control CompletedThis study tested a new drug called fazirsiran in 40 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The main goal was to see if the drug safely lowers levels of a harmful protein (Z-AAT) in the blood. Participants received multiple do…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:03 UTC